US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Qlife carries out a rights issue of approximately SEK 11.8 million and enters into an agreement for a credit facility of SEK 5.6 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREToday, the Board of Directors in Qlife Holding AB (“Qlife” or the “Company”) has, with the authorisation granted from the annual general meeting held on 26 June 2024, resolved to carry out an issue of 5,883,817 shares with

Qlife has signed a letter of intent with a top-20 global Pharma company to explore a potential commercial collaboration

Qlife has been in discussions with a top-20 global Pharma company to explore opportunities for the sales, distribution, and marketing of the Egoo Health platform, as well as to advance a potential commercial collaboration. The parties have signed a letter of intent (LOI); however, due to the early stage of negotiations, they have agreed to keep the company's identity confidential.Qlife is actively pursuing a partnership strategy and, with recent advancements in the Egoo Health product lines, expects to establish one or more partnerships during 2025. These collaborations will focus on the

Qlife announces introduction of a CE-approved joint developed Egoo Health platform for immediate sales

The company is pleased to announce that Qlife, in collaboration with its strategic partner Hipro Biotechnology, has developed a new Egoo Health product platform, which is already CE-IVD-marked. As a result, sales can commence immediately in the EU.Qlife and Hipro Biotechnology have joined forces to introduce a jointly developed, CE-IVD-marked platform to the market. This new solution combines the best of Hipro’s technology with Egoo Health’s innovations. It is based on Hipro’s already CE-IVD-marked Palm F product line, enhanced by Qlife’s high-tech Egoo optics, plasma-filtration, expertise,

Qlife provides sales and regulatory updates

The company has shifted its focus from research and development to becoming a sales-driven organization, emphasizing the distribution of its high-quality Egoo Health product platform in the rapidly expanding home diagnostics market. Qlife has successfully sold its RUO-approved Egoo Phenylalanine (Phe) system in seven countries and is currently conducting studies in the UK and Denmark to prepare submissions under IVDR EU regulations. These efforts aim to secure the necessary CE marking for the EU market, paving the way for full-scale commercialization. The following achievements in sales

Qlife provides update on operational progress in China

Since the summer, Qlife has been working diligently in close collaboration with its partner, Hipro Biotechnology, in China. The company is pleased to share the following updates: 1. Excellent clinical data for Egoo CRP in China 2. Additional biomarkers are advancing to the clinical testing phase 3. Hipro is preparing the production setup for the Egoo Analyzer ahead of market launch in China Excellent clinical data for CRP in China. Qlife's strategic partner in China, Hipro Biotechnology, has successfully completed an initial clinical study with excellent results. The final

The exercise period for warrants of series TO 5 in Qlife Holding begins today, 21 November 2024

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN, HONG KONG, SOUTH KOREA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA OR BELARUS OR ANY OTHER STATE OR JURISDICTION IN WHICH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES UNDER APPLICABLE LAW.The exercise period for warrants of series TO 5 that were issued in conjunction with Qlife Holding AB's ("Qlife" or the "Company") rights issue of units in February 2024 (the "Rights Issue")

Ny huvudansvarig revisor för Qlife Holding AB (publ)

Vid årsstämman den 26 juni 2024 valdes Göteborgs Revision Kommanditbolag (”Göteborgs Revision”) till revisionsbolag för Qlife Holding AB (publ) (”Qlife”). Göteborgs Revision utsåg Stefan Kylebäck till huvudansvarig revisor.Qlife har informerats om att Stefan Kylebäck kommer att efterträdas av Mattias Olofson som således kommer blir ny huvudansvarig revisor för Qlife. Bytet sker omgående. För ytterligare information vänligen kontakta:  Thomas Warthoe, VD Qlife Holding E-mail: tw@egoo.health Telefon: +45-21 63 35 34 Qlife is a Swedish company based in Helsingborg, which

Qlife announces outcome in directed issues

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN, HONG KONG, SOUTH KOREA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA OR BELARUS OR ANY OTHER STATE OR JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Qlife Holding AB (publ) (”Qlife” or the ”Company”) announces the outcome of the directed issues of shares and warrants to Warthoe Af 1967 ApS (owned by Thomas Warthoe, CEO), Altia Invest ApS (

Bulletin from the extraordinary general meeting, and the second control meeting, in Qlife Holding AB on 8 November 2024

Today, on 8 November 2024, an extraordinary general meeting, and the second control meeting, was held in Qlife Holding AB. A summary of the adopted resolutions follows below.Resolution on whether the company shall enter into liquidation or continue its operations It was noted that the second control balance sheet shows that the company's total equity is fully restored. On that basis, the extraordinary general meeting resolved in accordance with the primary proposal from the board of directors that the company’s operations shall be continued. Resolution on amendment of the Articles of

QLIFE HOLDING AB, Interim Report Q3, July to September 2024

Finally thereFinancial summary – third quarter 2024 · Revenue in the period amounted to kSEK 0 (45). · EBITDA for the period amounted to kSEK –27,151 (-6,660), and net loss kSEK – 28,087 (-8,926). · The total cash flow in the third quarter amounted to kSEK 2,979 (-3,631). · Earnings per share before/after dilution for the quarter amounted to SEK -0.12 (-0.01), calculated on weighted average number of shares in the period. Significant events – third quarter 2024 · On 2. July Qlife announces that it has participated a research trial in the USA for people living with PKU (

Kallelse till extra bolagsstämma i Qlife Holding AB tillika andra kontrollstämma

Aktieägarna i Qlife Holding AB, org.nr 559224-8040 (”Bolaget”), kallas till extra bolagsstämma, tillika andra kontrollstämma, den 8 november 2024 kl. 10.00 i Moll Wendén Advokatbyrås lokaler på Stortorget 8 i Malmö.Rätt att delta och anmälan Den som önskar delta i stämman ska: · dels vara upptagen som aktieägare i den av Euroclear Sweden AB framställda aktieboken avseende förhållanden på avstämningsdagen som är den 31 oktober 2024 · dels anmäla sig till stämman senast den 1 november 2024. Anmälan görs per post till Qlife Holding AB, Extra bolagsstämma, Redaregatan 48, 252 36

Qlife withdraws proposal to change company name

Qlife Holding AB (publ) (“Qlife” or the “Company”) has decided to withdraw its proposal to change the Company’s name as the intended name, Egoo Health AB, cannot be registered by the Swedish Companies Registration Office (Bolagsverket).On 29 August 2024, Qlife announced its intention to change the Company’s name to Egoo Health AB as part of a broader rebranding initiative. However, the Swedish Companies Registration Office has informed the Company that Egoo Health AB cannot be registered. As a result, Qlife has decided to withdraw the proposal to change its name. The Company remains

Qlife starts sales of its PHE rare disease test, addressing an unmet need in the at-home testing market worth SEK 2.5 billion

Resent due to technical problems news distributor. Since its inception, Qlife has been developing the Phenylalanine (PHE) test capsule and is now prepared to offer it for sale to individuals with Phenylketonuria. Initially, the at-home PHE test will be available as a research-use-only (CE-RUO) product, designed to supplement existing testing routines until it receives full regulatory approval. The company plans to begin the process of registering the test as an in-vitro diagnostic (IVD) later this year, starting in the UK and expanding to the EU and other markets.An at-home PHE test will

Qlife starts sales of its PHE rare disease test, addressing an unmet need in the at-home testing market worth SEK 2.5 billion

Since its inception, Qlife has been developing the Phenylalanine (PHE) test capsule and is now prepared to offer it for sale to individuals with Phenylketonuria. Initially, the at-home PHE test will be available as a research-use-only (CE-RUO) product, designed to supplement existing testing routines until it receives full regulatory approval. The company plans to begin the process of registering the test as an in-vitro diagnostic (IVD) later this year, starting in the UK and expanding to the EU and other markets.An at-home PHE test will significantly improve the quality of life for people

Qlife is pleased to announce that Peter Warthoe will return to the management group as Chief Scientific Officer

Peter Warthoe, one of the three founders of Qlife, is back in his management role as Chief Scientific Officer and will focus on the company’s continued quest to bring the Egoo Health self-testing diagnostic platform on the market.Peter Warthoe is one of the co-founders of Qlife but decided a few years ago to step out of the management role to focus more on his scientific projects. Given the company’s new lean structure and its focus on supporting its Chinese partner’s effort to bring products through clinical trials and to the market in China, Peter Warthoe will take up his role as CSO and

Qlife Holding AB (publ) is pleased to announce that it publishes a second balance sheet for liquidation purposes showing that the Company's total equity exceeds the registered share capital

Qlife Holding AB (publ) (“Qlife” or the “Company”) has, in accordance with Chapter 25, Section 16 of the Swedish Companies Act (“ABL”), prepared a second balance sheet for liquidation purposes, which has been reviewed by the Company's auditor. The balance sheet shows that the Company's total equity exceeds the registered share capital.On 21 March 2024, the Company presented a balance sheet for liquidation purposes, showing that the equity was less than half of the registered share capital. On 28 March 2024, Qlife announced that the rights issue, approved by the extraordinary general meeting

Production of Egoo consumables now established in China to support on-going clinical trials and future sales

Qlife Holding AB (publ) (“Qlife” or the “Company”) recently announced a restructuring and new financing to support its strategic goals. The Company is pleased to report that its operational plan with its partner Hipro Biotechnology (“Hipro”) in China is progressing as planned, with the production of Egoo consumables—EgooCapsule (Biochemistry reagents) and EgooCollect (Blood-to-Plasma filtration)—now established at the partner site. The target is to reach a capacity of 1 million in 2025 and 10 million within 3 years. This production capability will support clinical trial efforts and future

Qlife provides strategic business update and plans rebranding as 'Egoo Health' – a new era begins

Qlife Holding AB (publ) ("Qlife" or the "Company") is pleased to announce a comprehensive business update in light of recent strategic developments, including directed issues of shares and warrants, the repurchase of key assets from the estate of Qlife ApS, and an upcoming rebranding initiative, signaling the dawn of a new chapter for the Company.As outlined in the press release dated 29 August 2024, Qlife has successfully executed directed issues of shares and warrants pursuant to the authority granted by the annual general meeting 2024. These directed issues facilitate the repurchase of

Qlife acquires the assets of Qlife ApS, carries out directed issues of a total of approx. MSEK 6.90 and proposal of directed issues of approx. MSEK 5.05

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN, HONG KONG, SOUTH KOREA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA OR BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.Qlife Holding AB (publ) (“Qlife” or the “Company”) announces the acquisition of the assets of the Company's subsidiary Qlife ApS in bankruptcy, including goodwill and other intangible rights inventory, equipment, inventory and

QLIFE HOLDING AB, Interim Report Q2, April to June 2024

Restructuring the companyFinancial summary – second quarter 2024 · Revenue in the period amounted to kSEK 39 (46). · EBITDA for the period amounted to kSEK –8,002 (-16,287), and net loss kSEK –12,979 (-22,703). · The total cash flow in the second quarter amounted to kSEK -4,809 (7,894). · Earnings per share before/after dilution for the quarter amounted to SEK -0.01 (-0.05), calculated on weighted average number of shares in the period. Significant events – second quarter of 2024 · On 4. April Qlife enters its Danish subsidiary Qlife Aps into reconstruction. Under

Qlife Holding AB (publ) meddelar omräkning av teckningsoptioner

Med anledning av sammanläggningen av aktier i Qlife Holding AB (publ) (”Qlife” eller ”Bolaget”) som beslutades på årsstämman den 26 juni 2024, har omräkning gjorts i enlighet med optionsvillkoren avseende teckningskurs och antalet aktier som varje teckningsoption av serie TO 5 ger rätt att teckna.Årsstämman i Qlife beslutade den 26 juni 2024 om sammanläggning av aktier 1:2000, innebärande att 2000 befintliga aktier läggs samman till 1 aktie. Styrelsen i Qlife fastställde avstämningsdagen för sammanläggningen till den 31 juli. Med anledning av sammanläggningen har en omräkning genomförts

Qlife Holding AB’s subsidiary Qlife ApS terminates corporate restructuring and files for bankruptcy. Qlife Holding AB investigates a capital raise and to submit an offer to repurchase the assets.

Qlife Holding AB ("Qlife" or the "Company") has today received information that Qlife ApS’s reconstructor will terminate the corporate restructuring. The board of directors has consequently today decided to file for bankruptcy for the subsidiary, Qlife ApS. On 4 April 2024, the Company announced that Qlife ApS was undergoing reconstruction to address creditor issues and to manage short-term liquidity. Since then, the Company has been seeking a long-term financing solution to facilitate the subsidiary's exit from reconstruction. As announced on June 6, 2024, the Company had entered into a non-

Avstämningsdag för sammanläggning av aktier i Qlife Holding AB

Styrelsen i Qlife Holding AB (publ) (”Qlife” eller ”Bolaget”) har, med stöd av bemyndigandet från årsstämman som hölls den 26 juni 2024, beslutat att avstämningsdag för sammanläggning av aktier ska vara den 31 juli 2024. Genom sammanläggningen ska tvåtusen (2 000) befintliga aktier läggas samman till en (1) aktie.Sammanläggning av aktier Årsstämman beslutade den 26 juni 2024 om sammanläggning av aktier varigenom tvåtusen (2 000) befintliga aktier läggs samman till en (1) aktie. För att möjliggöra sammanläggningen beslutades även om ändring av bolagsordningens gränser för antalet aktier.

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media